Results 81 to 90 of about 1,029,181 (225)

N, N-Dimethyltryptamine and Biological Reductive Accounts for Religious and Spiritual Experiences [PDF]

open access: yes, 2014
There is unquestionably a plethora of details and mysteries regarding the mind and the body. However, with the advent of psychopharmacology (the study of how psychedelics inform or alter brain states), there are more issues at hand. Do psychedelics allow
Smith, Shaun
core   +1 more source

The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization [PDF]

open access: yes, 2016
Ayahuasca is an Amazonian psychoactive brew of two main components. Its active agents are β-carboline and tryptamine derivatives. As a sacrament, ayahuasca is still a central element of many healing ceremonies in the Amazon Basin and its ritual ...
Bokor, Petra   +2 more
core   +2 more sources

Safety pharmacology of acute mescaline administration in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber   +4 more
wiley   +1 more source

An ontogenic study of the behavioral effects of chronic intermittent exposure to ayahuasca in mice

open access: yesBrazilian Journal of Medical and Biological Research
Ayahuasca is a beverage obtained from decoctions of the Banisteriopsis caapi plus Psychotria viridis. In religious contexts, ayahuasca is used by different age groups.
N.F. Correa-Netto   +8 more
doaj   +1 more source

DMT alters cortical travelling waves

open access: yeseLife, 2020
Psychedelic drugs are potent modulators of conscious states and therefore powerful tools for investigating their neurobiology. N,N, Dimethyltryptamine (DMT) can rapidly induce an extremely immersive state of consciousness characterized by vivid and ...
Andrea Alamia   +4 more
doaj   +1 more source

Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775) [PDF]

open access: yes, 2018
Lysergic acid diethylamide (LSD) is perhaps one of the best-known psychoactive substances and many structural modifications of this prototypical lysergamide have been investigated. Several lysergamides were recently encountered as “research chemicals” or
Abramson   +67 more
core   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

open access: yesBritish Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander   +5 more
wiley   +1 more source

Psychedelics: A new era of treatment?

open access: yesEuropean Psychiatry, 2021
Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations.
S. Torres
doaj   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt   +3 more
wiley   +1 more source

Structural Pharmacology of Bufotenine Derivatives in Activating the 5-HT1A Receptor for Therapeutic Potential in Depression and Anxiety

open access: yesResearch
The 5-HT1A receptor is a critical target in the treatment of depression and anxiety. Bufotenine derivatives, such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), 5-hydroxy-N,N-dimethyltryptamine (5-OH-DMT), and 5-hydroxy-N,N,N-dimethyltryptamine—derived
Shu-jie Li   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy